Article Data

  • Views 344
  • Dowloads 166

Original Research

Open Access

Barriers to diagnosis and accessing effective treatment and support for testosterone deficiency

  • Janine David1,*,
  • Alexandra Charles2

1Primary Care Testosterone Advisory Group, DH1 2QW Durham, UK

2Besins Healthcare, WC1V 6NY London, UK

DOI: 10.22514/jomh.2024.001

Submitted: 23 August 2023 Accepted: 17 October 2023

Online publish date: 29 January 2024

*Corresponding Author(s): Janine David E-mail: Janine.david@wales.nhs.uk

Abstract

Testosterone deficiency is common but often undiagnosed and untreated with many men struggling with symptoms for years before reaching out for healthcare professional advice. In order to gain an holistic view of the barriers to men accessing effective treatment, this qualitative study captures the behaviours, beliefs and experiences of all key stakeholders: men with testosterone deficiency, general practitioners (GPs) and endocrinologists. The main findings include a lack of awareness and knowledge of the range of symptoms of testosterone deficiency amongst men and GPs, and stigma and embarrassment inhibiting open, proactive discussions between men and GPs and limiting diagnosis. Endocrinologists believe many men referred to them could be appropriately managed by GPs. Endocrinologists’ responsibility is to assess and provide appropriate treatment for more complicated cases, which often involves additional investigations that men are not expecting and might not result in treatment with testosterone therapy.


Keywords

Testosterone deficiency; Testosterone therapy; Patient research


Cite and Share

Janine David,Alexandra Charles. Barriers to diagnosis and accessing effective treatment and support for testosterone deficiency. Journal of Men's Health. 2024.doi:10.22514/jomh.2024.001.

References

[1] Hackett G, Kirby M, Rees RW, Jones TH, Muneer A, Livingston M, et al. The British society for sexual medicine guidelines on male adult testosterone deficiency, with statements for practice. The World Journal of Men’s Health. 2023; 41: 508–537.

[2] Salonia A, Bettocchi C, Carvalho J, Corona G, Jones TH, Kadioğlu A, et al.; European Association of Urology. EAU guidelines on sexual and reproductive health. 2022. Available at: https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Sexual-and-Reproductive-Health-2022_2022-03-29-084141_megw.pdf (Accessed: 13 January 2023).

[3] Mulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. International Journal Clinical Practice. 2006; 60: 762–769.

[4] Wiechno PJ, Kowalska M, Kucharz J, Sadowska M, Michalski W, Poniatowska G, et al. Dynamics of hormonal disorders following unilateral orchiectomy for a testicular tumor. Medical Oncology. 2017; 34: 84.

[5] Grossmann M, Matsumoto AM. A perspective on middle-aged and older men with functional hypogonadism: focus on holistic management. The Journal of Clinical Endocrinology & Metabolism. 2017; 102: 1067–1075.

[6] Cervoni E. NHS discrimination of testosterone deficiency syndrome. Trends in Urology and Men’s Health. 2020; 11: 23–26.

[7] Glaser BG, Strauss AL. The discovery of grounded theory. In Glaser BG, Strauss AL (eds.) The discovery of grounded theory (pp. 1–18). 1st edn. Routledge: New York. 2017.

[8] Hackett G, Kirby M, Edwards D, Jones TH, Rees J, Muneer A. UK policy statements on testosterone deficiency. International Journal of Clinical Practice. 2017; 71: e12901.

[9] Aceves‐Martins M, Quinton R, Brazzelli M, Cruickshank M, Manson P, Hudson J, et al. Identifying the outcomes important to men with hypogonadism: a qualitative evidence synthesis. Andrology. 2022; 10: 625–641.

[10] Gan EH, Pattman S, Pearce SHS, Quinton R. A UK epidemic of testosterone prescribing 2001–2010. Clinical Endocrinology. 2013; 79: 564–570.

[11] Sellke N, Omil-Lima D, Sun HH, Tay K, Rhodes S, Loeb A, et al. Trends in testosterone prescription during the release of society guidelines. International Journal of Impotence Research. 2023; 1–5.

[12] Stedman M, Livingston M, Albanese M, Hackett G, Heald AH. Hypogonadism is not being sufficiently recognised in 99% of general practices/family doctor surgeries. International Journal of Clinical Practice. 2020; 74: e13445.

[13] Heald AH, Stedman M, Whyte M, Livingston M, Albanese M, Ramachandran S, et al. Lessons learnt from the variation across 6741 family/general practices in England in the use of treatments for hypogonadism. Clinical Endocrinology. 2021; 94: 827–836.

[14] Lincoff AM, Bhasin S, Flevaris P, Mitchell LM, Basaria S, Boden WE, et al. Cardiovascular safety of testosterone-replacement therapy. New England Journal of Medicine. 2023; 389: 107–117.

[15] Dohle G, Arver S, Bettocchi C, Jones T, Kliesch S; European Association of Urology. EAU guidelines on male hypogonadism. 2019. Available at: https://d56bochluxqnz.cloudfront.net/media/EAU-Guidelines-on-Male-Hypogonadism-2019v2.pdf (Accessed: 22 September 2023).

[16] Corona G, Goulis DG, Huhtaniemi I, Zitzmann M, Toppari J, Forti G, et al. European academy of andrology (EAA) guidelines on investigation, treatment and monitoring of functional hypogonadism in males. Andrology. 2020; 8: 970–987.

[17] Hudson J, Cruickshank M, Quinton R, Aucott L, Aceves-Martins M, et al. Adverse cardiovascular events and mortality in men during testosterone treatment: an individual patient and aggregate data meta-analysis. The Lancet. Healthy Longevity. 2022; 3: e381–e393.


Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,200 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Directory of Open Access Journals (DOAJ) DOAJ is a unique and extensive index of diverse open access journals from around the world, driven by a growing community, committed to ensuring quality content is freely available online for everyone.

SCImago The SCImago Journal & Country Rank is a publicly available portal that includes the journals and country scientific indicators developed from the information contained in the Scopus® database (Elsevier B.V.)

Publication Forum - JUFO (Federation of Finnish Learned Societies) Publication Forum is a classification of publication channels created by the Finnish scientific community to support the quality assessment of academic research.

Scopus: CiteScore 0.7 (2022) Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.

Norwegian Register for Scientific Journals, Series and Publishers Search for publication channels (journals, series and publishers) in the Norwegian Register for Scientific Journals, Series and Publishers to see if they are considered as scientific. (https://kanalregister.hkdir.no/publiseringskanaler/Forside).

Submission Turnaround Time

Conferences

Top